Skip to content

MOTS-c vs Tesamorelin

Updated 9 sources

Key differences

  1. 1Tesamorelin has Phase 3 human data. MOTS-c has no human dose data.

Side by side

Facts from each record, in the same words as their own pages.
MOTS-c and Tesamorelin side by side
MOTS-cTesamorelin
Category
  • Longevity, Weight loss
  • GH axis
Evidence
  • Animal data only
  • Strong human trials
FDA status
  • Not FDA approvedRegulatory
  • FDA approved as Egrifta +2Regulatory
WADA
  • Prohibited
  • Prohibited
Half-life
  • Never measured in people. FDA found no in-vivo study, only a lab study showing fast breakdown in human blood. Figures of 1 to 6 hours on other sites are unsourced estimates.Clinical study
  • 8 minutes (Egrifta SV) and 11 minutes (Egrifta WR) in healthy subjects. Older figures for the original formulation are 26 to 38 minutes.Clinical study
Routes
  • Subcutaneous injection
  • Subcutaneous injection
Forms
  • Vial (powder)
Not reported
Reported doses
  • 0.8 to 10 mg (subcutaneous injection)
  • 200 to 1,000 mcg (subcutaneous injection)
  • 1 to 2 mg (subcutaneous injection)
  • 125 to 1,000 mcg (subcutaneous injection)
Most cited frequency
  • 2 to 3 times a week
  • Once daily
Vial sizes
  • 5 mg, 10 mg, 20 mg, 40 mgCompetitor guide
  • 2 mg, 5 mg, 10 mg, 20 mgCompetitor guide
Mixed vial keeps
  • Fridge, 2 to 8 C, never frozen.Competitor guide
  • Egrifta SV: use right after mixing and discard the rest.Competitor guide
Protocols on file
  • 16
  • 11

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

9 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Regulatory6

  1. FDA briefing document, PCAC July 23 to 24, 2026: MOTS-cFDA · checked Oct 23, 2026
  2. Egrifta SV labelDailyMed · checked Oct 23, 2026
  3. Egrifta WR labelDailyMed · checked Oct 23, 2026
  4. Interim 503A bulks listFDA · checked Oct 24, 2026